LGND
Income statement / Annual
Last year (2023), Ligand Pharmaceuticals Incorporated's total revenue was $131.31 M,
a decrease of 33.09% from the previous year.
In 2023, Ligand Pharmaceuticals Incorporated's net income was $52.15 M.
See Ligand Pharmaceuticals Incorporated’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$131.31 M
|
$196.25 M
|
$277.13 M
|
$186.42 M
|
$120.28 M
|
$251.45 M
|
$141.10 M
|
$108.97 M
|
$71.91 M
|
$64.54 M
|
| Cost of Revenue |
$11.56 M |
$52.83 M |
$62.18 M |
$30.42 M |
$11.35 M |
$6.34 M |
$5.37 M |
$5.57 M |
$5.81 M |
$9.14 M |
| Gross Profit |
$119.75 M |
$143.42 M |
$214.96 M |
$156.00 M |
$108.94 M |
$245.12 M |
$135.74 M |
$103.40 M |
$66.11 M |
$55.40 M |
| Gross Profit Ratio |
0.91 |
0.73 |
0.78 |
0.84 |
0.91 |
0.97 |
0.96 |
0.95 |
0.92 |
0.86 |
| Research and Development
Expenses |
$24.54 M
|
$36.08 M
|
$69.01 M
|
$59.39 M
|
$55.91 M
|
$27.86 M
|
$26.89 M
|
$21.22 M
|
$13.38 M
|
$12.12 M
|
| General & Administrative
Expenses |
$52.79 M
|
$70.06 M
|
$57.48 M
|
$64.44 M
|
$41.88 M
|
$37.73 M
|
$28.65 M
|
$26.62 M
|
$24.38 M
|
$22.57 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$52.79 M
|
$70.06 M
|
$57.48 M
|
$64.44 M
|
$41.88 M
|
$37.73 M
|
$28.65 M
|
$26.62 M
|
$24.38 M
|
$22.57 M
|
| Other Expenses |
-$32.61 M |
$34.24 M |
$9.57 M |
$23.44 M |
$16.86 M |
$15.79 M |
$12.12 M |
$10.64 M |
-$10.03 M |
-$3.19 M |
| Operating Expenses |
$109.93 M |
$140.38 M |
$136.06 M |
$147.27 M |
$114.66 M |
$81.39 M |
$67.66 M |
$58.49 M |
$37.76 M |
$34.69 M |
| Cost And Expenses |
$121.49 M |
$193.21 M |
$198.24 M |
$177.69 M |
$126.00 M |
$87.73 M |
$73.03 M |
$64.06 M |
$43.57 M |
$43.83 M |
| Interest Income |
$7.06 M |
$2.05 M |
$886,000.00 |
$8.08 M |
$28.43 M |
$14.00 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$656,000.00 |
$1.80 M |
$18.74 M |
$27.42 M |
$35.75 M |
$48.28 M |
-$11.40 M |
-$12.18 M |
-$11.80 M |
-$4.86 M |
| Depreciation &
Amortization |
$37.41 M
|
$43.39 M
|
$41.34 M
|
$27.97 M
|
$43.73 M
|
$16.69 M
|
$12.52 M
|
$11.29 M
|
$2.63 M
|
$2.66 M
|
| EBITDA |
$51.22 M
|
$8.73 M
|
$117.20 M
|
$31.99 M
|
-$804.54 M
|
$179.52 M
|
$82.78 M
|
$59.93 M
|
$6.19 M
|
$26.93 M
|
| EBITDA Ratio |
0.39 |
0.04 |
0.42 |
0.17 |
-6.69 |
0.71 |
0.59 |
0.55 |
0.09 |
0.42 |
| Operating Income Ratio
|
0.07
|
-0.13
|
0.28
|
0.05
|
-0.05
|
0.65
|
0.48
|
0.4
|
0.38
|
0.3
|
| Total Other
Income/Expenses Net |
$53.84 M
|
$61.51 M
|
-$31.60 M
|
-$19.09 M
|
$802.36 M
|
$43.88 M
|
-$10.85 M
|
-$36.96 M
|
$6.98 M
|
-$9.41 M
|
| Income Before Tax |
$63.66 M |
$36.01 M |
$47.30 M |
-$10.54 M |
$796.64 M |
$173.33 M |
$57.23 M |
$7.96 M |
$35.33 M |
$11.30 M |
| Income Before Tax Ratio
|
0.48
|
0.18
|
0.17
|
-0.06
|
6.62
|
0.69
|
0.41
|
0.07
|
0.49
|
0.18
|
| Income Tax Expense |
$9.84 M |
$41.23 M |
-$10.29 M |
-$7.55 M |
$167.34 M |
$30.01 M |
$44.68 M |
$10.33 M |
-$219.60 M |
$410,000.00 |
| Net Income |
$52.15 M |
-$5.22 M |
$57.14 M |
-$2.99 M |
$629.30 M |
$143.32 M |
$12.56 M |
-$1.64 M |
$257.31 M |
$12.02 M |
| Net Income Ratio |
0.4 |
-0.03 |
0.21 |
-0.02 |
5.23 |
0.57 |
0.09 |
-0.02 |
3.58 |
0.19 |
| EPS |
3.02 |
-0.31 |
3.44 |
-0.18 |
33.13 |
5.96 |
0.6 |
-0.0785 |
13 |
0.59 |
| EPS Diluted |
2.94 |
-0.31 |
3.31 |
-0.18 |
31.85 |
5.96 |
0.53 |
-0.0785 |
12.12 |
0.56 |
| Weighted Average Shares
Out |
$17.30 M
|
$16.87 M
|
$16.63 M
|
$16.18 M
|
$19.00 M
|
$24.05 M
|
$21.03 M
|
$20.83 M
|
$19.79 M
|
$20.42 M
|
| Weighted Average Shares
Out Diluted |
$17.76 M
|
$16.87 M
|
$17.25 M
|
$16.18 M
|
$19.76 M
|
$24.07 M
|
$23.48 M
|
$20.83 M
|
$21.23 M
|
$21.43 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
